<DOC>
	<DOCNO>NCT02263547</DOCNO>
	<brief_summary>Primary Objective To determine colestipol hydrochloride tablet accelerate elimination teriflunomide . Teriflunomide administer 14 day follow colestipol dose 11 day . Total duration study 40 day . Secondary Objectives To collect information pattern side effect use colestipol hydrochloride teriflunomide administration determine best duration therapy need adequate elimination</brief_summary>
	<brief_title>Rapid Elimination Procedure Teriflunomide With Colestipol Hydrochloride</brief_title>
	<detailed_description>participant follow 40 day allow time administer load dose teriflunomide observe elimination drug use colestipol hcl .</detailed_description>
	<mesh_term>Colestipol</mesh_term>
	<criteria>To eligible entry study , candidate must meet following eligibility criterion time baseline visit : 1 . Participants provide informed consent signature inform consent form : informed consent process complete full discussion requirement possible risk . 2 . Healthy volunteer* 3 . Aged 1845 year , inclusive 4 . Body Mass Index 1829 kg/m2 ( body weight 4085 kg woman 5095 kg men ) *Healthy volunteer define free concomitant medication use either treatment , deem Investigator , contraindicate past medical history participant . 1 . Current smoker past history smoker . 2 . Unable provide inform consent participate study Such mental condition render participant unable understand nature , scope , possible consequence study 3 . Participant unlikely comply protocol determine Investigator , eg , uncooperative attitude , inability return followup visit 4 . Clinically relevant cardiovascular , hepatic , neurological , endocrine , major systemic disease make implementation protocol interpretation study result difficult would put participant risk participate study 5 . Persistent significant severe infection , either acute chronic 6 . Recent history drug alcohol abuse within past 6 month ( participant ask refrain alcohol drug use course study ) 7 . Participant Investigator Subinvestigator , research assistant , pharmacist , study coordinator , staff relative thereof , directly involve conduct protocol 8 . Prior use investigational drug precede 6 month 9 . Liver function impairment persist elevation ( confirm retest ) alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , direct bilirubin great 2x upper limit normal range ( ULN ) . 10 . Pregnant breastfeed woman plan become pregnant study 11 . Women childbearing potential protected effective contraceptive method birth control and/or unwilling unable test pregnancy . 12 . Participants wish parent child ( partner conception child ) course trial . 13 . Participants significantly impair bone marrow function significant anemia , leukopenia , thrombocytopenia ( confirm retest ) : Hematocrit &lt; 35 % and/or Absolute white blood cell count &lt; 3000 cells/mm3 ( μL ) and/or Platelet count &lt; 150 000 cells/mm3 ( μL ) and/or Absolute neutrophil ≤ 1500 cells/mm3 ( μL ) 14 . Any known history severe preexist constipation 15 . History swallow disorder difficulty swallow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>teriflunomide</keyword>
	<keyword>colestipol hcl</keyword>
</DOC>